{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:40:07Z","timestamp":1787593207426,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00259-019-04674-0","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T17:02:36Z","timestamp":1578070956000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide"],"prefix":"10.1007","volume":"47","author":[{"given":"Florian","family":"Rosar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Dewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Khreish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Bohnenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Linxweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Ohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-3375","authenticated-orcid":false,"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"4674_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"4674_CR2","first-page":"3874","volume":"41","author":"M Kuriyama","year":"1981","unstructured":"Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 1981;41:3874\u20136.","journal-title":"Cancer Res"},{"key":"4674_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/1097-0045(20000915)45:1<19::AID-PROS3>3.0.CO;2-M","volume":"45","author":"B Candas","year":"2000","unstructured":"Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, L\u00e9vesque J, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate. 2000;45:19\u201335.","journal-title":"Prostate."},{"key":"4674_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.annepidem.2018.03.001","volume":"28","author":"J Li","year":"2018","unstructured":"Li J, Siegel DA, King JB. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004\u20132014. Ann Epidemiol. 2018;28:328\u201330.","journal-title":"Ann Epidemiol"},{"key":"4674_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","volume":"68","author":"PA Kupelian","year":"2006","unstructured":"Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68:593\u20138.","journal-title":"Urology"},{"key":"4674_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KA Roehl","year":"2004","unstructured":"Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910\u20134.","journal-title":"J Urol"},{"key":"4674_CR7","first-page":"CD003506","volume":"6","author":"F Kunath","year":"2019","unstructured":"Kunath F, Jensen K, Pinart M, Kahlmeyer A, Schmidt S, Price CL, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2019;6:CD003506.","journal-title":"Cochrane Database Syst Rev"},{"key":"4674_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review: the epidemiology of CRPC. Int J Clin Pract. 2011;65:1180\u201392.","journal-title":"Int J Clin Pract"},{"key":"4674_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"4674_CR10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, Horti J, Oudard S, James ND, Rosenthal MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"4674_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242\u20135.","journal-title":"J Clin Oncol"},{"key":"4674_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"4674_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"4674_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bju.13123","volume":"117","author":"J Schalken","year":"2016","unstructured":"Schalken J, Fitzpatrick JM. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. 2016;117:215\u201325.","journal-title":"BJU Int"},{"key":"4674_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"4674_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"4674_CR17","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4674_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","volume":"44","author":"MP Yadav","year":"2017","unstructured":"Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4674_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339.","journal-title":"J Cell Biochem"},{"key":"4674_CR20","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545\u201352.","journal-title":"J Nucl Med"},{"key":"4674_CR21","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.18632\/oncotarget.12240","volume":"8","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Reinhardt S, Ilhan H, Delker A, B\u00f6ning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8:3581\u201390.","journal-title":"Oncotarget."},{"key":"4674_CR22","doi-asserted-by":"publisher","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","volume":"57","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S\u201389S.","journal-title":"J Nucl Med"},{"key":"4674_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","volume":"43","author":"YJ Kim","year":"2018","unstructured":"Kim YJ, Kim Y. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis. Clin Nucl Med. 2018;43:728\u201334.","journal-title":"Clin Nucl Med"},{"key":"4674_CR24","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA radioligand therapy for prostate cancer. J Nucl Med. 2017;58:1196\u2013200.","journal-title":"J Nucl Med"},{"key":"4674_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/pros.23522","volume":"78","author":"B Kranzb\u00fchler","year":"2018","unstructured":"Kranzb\u00fchler B, Salemi S, Umbricht CA, M\u00fcller C, Burger IA, Sulser T, et al. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate. 2018;78:758\u201365.","journal-title":"Prostate."},{"key":"4674_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","volume":"5","author":"B Meller","year":"2015","unstructured":"Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66.","journal-title":"EJNMMI Res"},{"key":"4674_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","volume":"8","author":"K L\u00fcckerath","year":"2018","unstructured":"L\u00fcckerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8:96.","journal-title":"EJNMMI Res"},{"key":"4674_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.116.181800","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81\u20134.","journal-title":"J Nucl Med"},{"key":"4674_CR29","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4674_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pros.22910","volume":"75","author":"JD Murga","year":"2015","unstructured":"Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer: synergy targets: PSMA and androgen receptor. Prostate. 2015;75:242\u201354.","journal-title":"Prostate."},{"key":"4674_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78\u201382.","journal-title":"Eur Urol Oncol"},{"key":"4674_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med. 2019;60:950\u20134.","journal-title":"J Nucl Med"},{"key":"4674_CR33","doi-asserted-by":"crossref","unstructured":"Wondergem M, van der Zant F, Broos W, Knol R. Increased PSMA Expression in castration-resistant prostate cancer metastases 3 months after initiation of enzalutamide indicated by 18F-DCFPyL PET\/CT. Clin Nucl Med. 2019:1.","DOI":"10.1097\/RLU.0000000000002585"},{"key":"4674_CR34","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00259-008-0875-1","volume":"35","author":"A Schaefer","year":"2008","unstructured":"Schaefer A, Kremp S, Hellwig D, R\u00fcbe C, Kirsch C-M, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35:1989\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4674_CR35","doi-asserted-by":"publisher","first-page":"e105682","DOI":"10.1371\/journal.pone.0105682","volume":"9","author":"K Hirata","year":"2014","unstructured":"Hirata K, Kobayashi K, Wong K-P, Manabe O, Surmak A, Tamaki N, et al. A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One. 2014;9:e105682.","journal-title":"PLoS One"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04674-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:13:57Z","timestamp":1609546437000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04674-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4674"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04674-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"6 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the patients described herein were in accordance with the ethical standards of the Institutional and\/or National Research Ethics Committees and with the 1964 Helsinki Declaration and its later amendments, or with comparable ethical standards. This report does not include any animal studies. Written informed consent was obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients have given written consent to publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}